Where do we stand with immune checkpoint blockade for advanced cutaneous squamous cell carcinoma? A systematic review and critical appraisal of the existing evidence
Open Access
- 1 August 2020
- journal article
- letter
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 183 (2), 380-382
- https://doi.org/10.1111/bjd.18957
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trialThe Lancet Oncology, 2020
- Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.Journal of Clinical Oncology, 2019
- Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN.Journal of Clinical Oncology, 2019
- Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma: An updated analysis.Journal of Clinical Oncology, 2019
- Cemiplimab: First Global ApprovalDrugs, 2018
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaNew England Journal of Medicine, 2018